The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXIV.ad

Pulmonary alveolar proteinosis (PAP) (secondary)

See also under 'PAP pattern' for drugs which may cause the condition

Publications

Du EZ, Yung GL, Le DT, Masliah E, Yi ES, Friedman PJ

Severe alveolar proteinosis following chemotherapy for acute myeloid leukemia in a lung allograft recipient.

Journal of thoracic imaging. 2001;16(4):307-9

Aymard JP, Gyger M, Lavallee R, Legresley LP, Desy M

A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung?

Cancer. 1984;53(4):954-6

Hankins DG, Sanders S, MacDonald FM, Drage CW

Pulmonary toxicity recurring after a six week course of busulfan therapy and after subsequent therapy with uracil mustard.

Chest. 1978;73(3):415-6